Business
VAXXA: Q1 2026 revenue surged 50% year-over-year, but losses widened amid higher personnel costs
VAXXA: Q1 2026 revenue surged 50% year-over-year, but losses widened amid higher personnel costs
About this update from Vaxxa Ab
Revenue grew nearly 50% year-over-year in Q1 2026, driven by new customers and marketing, but losses widened due to higher personnel costs. Positive cash flow was achieved, and the outlook remains focused on scaling and margin improvement.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.